News
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Topline data for RECOVER trial on track for October 2023CUPERTINO, Calif., Sept. 25, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical...
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 07, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia - - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - CUPERTINO, Calif., Aug. 17,...
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 - - Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 - CUPERTINO, Calif., Aug. 14, 2023...
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
CUPERTINO, Calif., July 31, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Pharmaceuticals to be Added to Russell Microcap® Index
CUPERTINO, Calif., June 26, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
- Enrollment ongoing at multiple sites in the US, Europe, and Asia - - Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia symptoms as well as accompanying neuroinflammation - - Topline data for...
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June
CUPERTINO, Calif., June 15, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives
Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved survival and lung function, and reduced lung fibrosis and inflammation in a bleomycin-induced rodent...
Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting
Data reinforce brilaroxazine's differentiated clinical pharmacology and safety profile Brilaroxazine may be co-administered with other drugs metabolized by CYP3A inhibitors Metabolism and excretion profiles of brilaroxazine were similar across mice, canines, and...